Daewoong Pharmaceutical announced that Nabota, its botulinum toxin product, has surpassed 1 trillion Korean won (approximately $750 million USD) in cumulative lifetime sales. The milestone underscores robust demand for Nabota across Asia-Pacific and emerging markets, where it competes alongside Botox, Dysport, and regional alternatives.
Market
Daewoong's Nabota Crosses 1 Trillion Won in Cumulative Sales—Asian Toxin Gains Scale
South Korean neuromodulator reaches major sales milestone, signaling sustained demand outside North America.
1-YEAR MOVE
ABBV
▲11.6%
| Ticker | Company | 1-year change |
|---|---|---|
| ABBV | AbbVie (Allergan Aesthetics) | +11.6% |
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Nabota's 1 trillion won milestone reflects sustained demand for non-Allergan toxins in Asia-Pacific.
Nabota's success reflects both strong brand recognition in South Korea and Japan, and successful market penetration in Southeast Asia and China. While Nabota remains largely absent from U.S. practices, the milestone signals that non-Allergan/Galderma toxins can achieve substantial scale in international markets. For U.S. practice owners, the data reinforces that the global neuromodulator market is increasingly fragmented, with regional players building defensible positions outside North America.
Source: original report ↗
Frequently asked questions
What is Nabota and how much has it sold?
Nabota is a botulinum toxin product made by South Korean pharmaceutical company Daewoong. It has surpassed 1 trillion Korean won (approximately $750 million USD) in cumulative lifetime sales, making it a major player in Asian and emerging markets.
Is Nabota available in the United States?
No, Nabota remains largely absent from U.S. medical aesthetics practices. It has achieved its scale primarily through strong market penetration in South Korea, Japan, Southeast Asia, and China rather than North American distribution.
How does Nabota compare to Botox and Dysport?
Nabota competes directly with Botox and Dysport in Asia-Pacific and emerging markets, but operates in a different geographic space than these brands. While Botox and Dysport dominate North America, Nabota has built a defensible regional position by establishing strong brand recognition in South Korea and Japan first, then expanding into Southeast Asia and China.
What does Nabota's 1 trillion won milestone mean for the global neuromodulator market?
The milestone demonstrates that non-Allergan and non-Galderma toxins can achieve substantial scale and profitability in international markets. It signals that the global neuromodulator market is increasingly fragmented, with regional players building strong positions outside North America rather than remaining dominated solely by Western brands.
Which countries drive Nabota's sales?
Nabota has achieved strong brand recognition and market penetration in South Korea, Japan, Southeast Asia, and China. These regions represent the core markets where Daewoong has built its customer base and achieved the 1 trillion won sales milestone.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.